NEJM article on diagnosis of Burkitts lymphoma with important contributions from the Lymphoma Group

E.B. Smeland
E.B. Smeland
An article entitled “Molecular Diagnosis of Burkitt's Lymphoma” was recently published in the prestiguous journal New England Journal of Medicine (impact factor 44.0). The authors conclude that gene-expression profiling is an accurate, quantitative method for distinguishing Burkitt's lymphoma from diffuse large-B-cell lymphoma, and that this method identifies patients who are curable with intensified chemotherapeutic regimens.
The work has been carried out by the “Lympoma and leukemia molecular profiling project” (LLMPP), a consortium consisting of eight international lymphoma groups in Europe, USA and Canada. The Nordic countries is represented in the LLMPP through the lymphoma group at the Norwegian Radium Hospital, whose members Erlend B. Smeland, Harald Holte, Svein Kvaløy and Jan Delabie co-authored the article. Smeland (photo) is the leader of the Norwegian part of the project.

Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ, Greiner TC, Weisenburger DD, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Delabie J, Rimsza LM, Braziel RM, Grogan TM, Campo E, Jaffe ES, Dave BJ, Sanger W, Bast M, Vose JM, Armitage JO, Connors JM, Smeland EB, Kvaloy S, Holte H, Fisher RI, Miller TP, Montserrat E, Wilson WH, Bahl M, Zhao H, Yang L, Powell J, Simon R, Chan WC, Staudt LM; Lymphoma/Leukemia Molecular Profiling Project. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med. 2006 Jun 8;354(23):2431-42. (link to PubMed)

Home page of the Lymphoma Group at the Norwegian Radium Hospital (

Home page of Erlend B. Smelands group (

About the Lymphoma/Leukemia molecular profiling project (LLMPP) (from

Gir aggressive lymfomer en genprofil. Article (in Norwegian) about the findings in the NEJM publication (from - Tidsskr Norsk Laegefor)

Page visits: 7158